The purchase price, and that is confidential and was negotiated for a maximum of 300 huge number of doses, is somewhat less than the $19.50 a photo the United States agreed to buy a very first shipment of hundred million doses of the same vaccine, in line with what Reuters reported in November.
The EU booklet dated Nov. eighteen was circulated internally right after the EU announced its supply package with Pfizer and the German partner BioNTech of its on Nov. eleven.
The EU drug regulator is anticipated to determine on Monday on approval for the Pfizer vaccine after the shot was authorised in a number of countries, including Britain and the United States.
On Thursday Belgian declare secretary with the spending budget Eva De Bleeker printed on Twitter a table with price tags Belgium will shell out pharmaceutical companies for their COVID 19 vaccines. She retracted the piece of writing shortly after publishing.
In that dinner table the Pfizer vaccine was suggested as costing Belgium twelve euros ($14.6) per dose, top many to think this was the total fee agreed with the EU.
Various other vaccines in the table were also shown with prices lower compared to prices disclosed by EU solutions.
“There is surely a complete fee along with a price upon delivery,” an EU official involved in talks with vaccine makers told Reuters when directed to clarify the big difference between the Belgian and EU prices.
A spokesman for De Bleeker declined to comment on Monday, citing confidentiality requirements, but pointed to what De Bleeker told the Belgian parliament previous week. In that public hearing, De Beeker stated Belgium’s budgeted prices were still partial.
Under EU advanced purchase deals for COVID 19 vaccines, the bloc concurs initial payments with business enterprises to secure doses before they are approved. After approvals, EU governments are able to pay the rest to get reserved doses.
The EU hasn’t revealed the initial payment agreed with Pfizer.
However, it said in October that it paid about 1 billion euros inside downpayments to AstraZeneca, Sanofi and Johnson & Johnson for the shots of theirs, with a further 1.45 billion euros budgeted for initial payments to Pfizer BioNTech, Curevac and Moderna.
It has since agreed source deals with all six companies and is negotiating a seventh arrangement with Novavax.